DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

Bend, Oregon, UNITED STATES


BEND, Ore., June 16, 2021 (GLOBE NEWSWIRE) --

Ap19

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1.    KEY INFORMATION

Name of person dealing (Note 1)Stonepine Capital, L.P.
Company dealt inStrongbridge Biopharma plc
Class of relevant security to which the dealings being disclosed relate (Note 2)Ordinary Shares
Date of dealingSale - 16/06/2021

2.    INTERESTS AND SHORT POSITIONS


(a)    Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

 LongShort
 Number (%)Number (%)
(1) Relevant securities3,027,973 4.47%0
(2) Derivatives (other than options)   00
(3) Options and agreements to purchase/sell   00
Total3,027,973 4.47%0

(b)    Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:LongShort
 Number (%)Number (%)
(1) Relevant securitiesN/AN/A


(2) Derivatives (other than options)
N/AN/A


(3) Options and agreements to purchase/sell
N/AN/A
TotalN/AN/A

Ap20

1.    DEALINGS (Note 4)


(a)    Purchases and sales

Purchase/saleNumber of relevant securitiesPrice per unit (Note 5)
Sale

(51,200)$2.9188



(b)    Derivatives transactions (other than options transactions)

Product name,

e.g. CFD
Nature of transaction

(Note 6)
Number of relevant securities

(Note 7)
Price per unit

(Note 5)
    

(c)    Options transactions in respect of existing relevant securities

(i)    Writing, selling, purchasing or varying

Product name,
e.g. call option
Writing, selling, purchasing, varying etc.Number of securities to which the option relates (Note 7)Exercise priceType, e.g. American, European etc.Expiry dateOption money paid/received per unit (Note 5)
       

(ii)    Exercising

Product name,

e.g. call option
Number of securitiesExercise price per unit (Note 5)
   

(d)    Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction

(Note 8)
DetailsPrice per unit

(if applicable) (Note 5)
   

Ap21

2.    OTHER INFORMATION

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
None

Agreements, arrangements or understandings relating to options or derivatives

Is a Supplemental Form 8 attached? (Note 9)                                            NO

Date of disclosure16 June 2021
Contact nameJeff Nunnenkamp
Telephone number+1 541-647-5673
If a connected EFM, name of offeree/offeror with which connectedN/A
If a connected EFM, state nature of connection (Note 10)N/A